Presentation TCT 2019

TCT 13: Alirocumab improve coronary plaque vulnerability: first randomized control trial to assess the effect of alirocumab for plaque vulnerabilityusing optical coherence tomography.

Presenter: yoichiro sugizaki

September 25, 2019

REGISTER for free or LOG IN to view this content

TCT 13: Alirocumab improve coronary plaque vulnerability: first randomized control trial to assess the effect of alirocumab for plaque vulnerabilityusing optical coherence tomography.

Coronary

Presentation

TCT 2019

Plaque Modification

Up Next

Presentation TCT 2019

TCT 14: Assessment of the Sources of Near-infrared Auto-fluorescence in High-risk Coronary Artery Plaques: a Histopathologic Correlative Study

Presenter: Mie Kunio

September 25, 2019

More slides +

Presentation TCT 2019

TCT 15: Prognostic Impact of Healed Coronary Plaque in Non-culprit Segments Assessed by Optical Coherence Tomography

Presenter: Eisuke Usui

September 25, 2019

Presentation TCT 2019

Keynote Lecture: Robotics in Interventional CV Procedures — Lessons Learned From the Surgical Field

Presenter: Fred Moll

September 25, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.